Statins and prostate cancer prevention: where we are now, and future directions.
Statins are cholesterol-lowering drugs that are widely used to prevent and treat atherosclerotic cardiovascular disease. Recent research from both in vitro and in vivo studies suggests that there is an association between the use of statins and a reduction in the incidence of and mortality from prostate cancer. Several mechanisms of action that might bring about these beneficial effects of statins have been proposed, most of which include direct effects of statins on intracellular signaling. In this Review we discuss the current knowledge on the use of statins to prevent prostate cancer. We will also look at future directions for clinical research on this topic.
Murtola
Teemu J
TJ
Department of Epidemiology, School of Public Health, University of Tampere, Tampere, Finland. teemu.murtola@uta.fi
Visakorpi
Tapio
T
Lahtela
Jorma
J
Syvälä
Heimo
H
Tammela
Teuvo Lj
TLj
D000818:Animals; D017209:Apoptosis / Q000502:physiology; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000517:prevention & control; D002453:Cell Cycle / Q000502:physiology; D015897:Comorbidity; D018450:Disease Progression; D020690:GTPase-Activating Proteins / Q000502:physiology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000188:drug therapy / Q000453:epidemiology; D008297:Male; D015201:Meta-Analysis as Topic; D008798:Mevalonic Acid / Q000627:therapeutic use; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control*; D020703:ras GTPase-Activating Proteins / Q000502:physiology
D020690:GTPase-Activating Proteins; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D020703:ras GTPase-Activating Proteins; C085379:rho GTPase-activating protein; D017430:Prostate-Specific Antigen; D008798:Mevalonic Acid